Liraglutide Effectiveness in Preoperative Weight-loss for Bariatric-metabolic Surgery

NCT06201819 on ClinicalTrials.gov · last registry update 2024-01-18

A small phase 4 — 37 participants, against a typical 75. The sponsor logged completion for 18 March 2023. Primary outcome, as filed: Preoperative weight changes. liraglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Hospital Civil Juan I. Menchaca
Sponsor type: Other
Enrollment: 37
Started: 2022-12-18
Primary completion: 2023-03-18 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Preoperative weight changes

Conditions studied

Weight Loss · Bariatric Surgery Candidate · Obesity, Morbid

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.